Navigation Links
Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
Date:5/24/2013

or expectations of profit attributable to shareholders; anticipated provisions or write-downs, economic profit, dividends, capital structure or any other financial items or ratios; statements of plans, objectives or goals of Elan, the Elan Group, RP Management or Royalty Pharma following the Increased Offer; statements about the future trends in interest rates, liquidity, foreign exchange rates, stock market levels and demographic trends and any impact that those matters may have on Elan, the Elan Group, RP Management or Royalty Pharma following the Increased Offer; statements concerning any future Irish, US or other economic environment or performance; statements about strategic goals, competition, regulation, regulatory approvals, dispositions and consolidation or technological or regulatory developments; and statements of assumptions underlying such statements.

Forward looking statements only speak as of the date on which they are made, and the events discussed in this announcement may not occur. Subject to compliance with applicable law and regulation, Royalty Pharma is not under any obligation to update publicly or revise forward looking statements, whether as a result of new information, future events or otherwise.

Additional Information

This announcement is not a substitute for the Revised Offer Document and the Revised Acceptance Documents or any other document that Royalty Pharma has filed and may file with the Securities and Exchange Commission ("SEC") (including the Original Offer Document) in connection with the Offer.  ELAN STOCKHOLDERS ARE URGED TO READ ANY SUCH DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE INCREASED OFFER.  Any such documents will be available free of charge through the website maintained by the SEC at www.sec.gov or by directing a request to any of the persons listed above.

The Offer is and will be m
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share
2. Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash
3. Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
4. PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
5. Royalty Rates for Pharmaceuticals & Biotechnology: Real-Deal Information for Hundreds of Transactions
6. PDL BioPharma Provides First Quarter 2013 Royalty Revenue Guidance of $92 Million
7. Royalty Pharma Announces Proposal To Acquire Elan
8. Royalty Rates Take Center Stage in Biopharma Dealmaking
9. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
10. Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
11. Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... to the announced tender offer for all of the outstanding shares ... of the waiver, the transaction is no longer conditional on OFT ... 24, 2014 following the currently scheduled expiration time, subject to the ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... to the American Cancer Association, prostate cancer affects one ... second leading cause of cancer deaths in men. When ... than 90 percent, making swift treatment key. (See ... however, can be limited and affect quality of life ...
... New Surgery Technique Impacting the Treatment of Women,s Cancers?CHICAGO, ... the fastest growing technological advances in the field of ... surgery (MIS) technique, its impact on the profession, and ... will be some of the topics discussed during the ...
Cached Medicine Technology:VIDEO from Medialink and International HIFU: New Prostate Cancer Procedure Being Tested in US Clinical Trials 2Society of Gynecologic Oncologists 40th Annual Meeting on Women's Cancer to Include Sessions on Robotics Surgery 2Society of Gynecologic Oncologists 40th Annual Meeting on Women's Cancer to Include Sessions on Robotics Surgery 3
(Date:4/16/2014)... , While it is well known that fertility treatments ... and that multiples are at elevated risk of premature ... in Fertility and Sterility . The ... can reduce the odds of multiple births and prematurity, ...
(Date:4/15/2014)... decades-old medical mystery and in the process have found a ... about 1.5 million people a year. The researchers say they now ... has been in use for more than 50 years even ... is to the microbes it attacks. , A report ...
(Date:4/14/2014)... advances have been made in chemotherapy over the past ... healthy tissues continues to be a major challenge. ... delivery, including the use of nanocarriers, or capsules, that ... in the body. , The catch? These carriers are ...
(Date:4/14/2014)... American Associations for Dental Research (IADR/AADR) have published a ... and Craniofacial Manifestations." The complete review by researchers Sunday ... Collins, Brian L. Foster, Rachel I. Gafni, Janice S. ... Timothy Wright is published in the OnlineFirst portion of ...
(Date:4/14/2014)... treatment decisions leaves cancer patients feeling more satisfied with ... the experience, researchers from the Perelman School of ... the journal Cancer . , In a study ... MD , an associate professor in the department in ...
Breaking Medicine News(10 mins):Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Nano shake-up 2Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3
... with CyberKnife Radiosurgery Worldwide, SUNNYVALE, Calif., Nov. ... global leader in the field of radiosurgery,today announced ... to treat more than 4,000 lung cancer patients ... patients in total have been treated,with CyberKnife radiosurgery ...
... 25% of all,cancers are due to genetic factors, patients that ... on the lookout for the early warning signs of,cancer. This ... from,both a medical and psychological prospective. Cancer does run ... Today, suggests it is misleading to think of cancer as ...
... (NYSE: SGP ) today announced that it ... Commission (FTC) regarding its,planned acquisition of Organon BioSciences ... 2007. Organon BioSciences is comprised mainly of ... health business. It also,includes Nobilon, the human vaccine ...
... of Georgia Drug Agency Approves Protocol for New Clinical ... of Bavituximab in Combination with ... Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company ... C virus (HCV) infection, today announced that its Phase ...
... following is being,issued by the National Council on Disability:, ... to December 1, 2007., WHERE:, Hyatt Regency Boston ... November 29, 2007, 8:30 a.m. - 10:00 a.m. ... Vaughn -- Introduction of Council Members, NCD staff and ...
... 16 21st Services has created its,first Medical Advisory ... an innovative approach in the life settlement industry. ... the sophistication,of its underwriting model and its life expectancy ... up of physicians from,across the country who are experts ...
Cached Medicine News:Health News:Accuray Exceeds 4,000 Lung Cancer Patients Treated with CyberKnife(R) System 2Health News:Accuray Exceeds 4,000 Lung Cancer Patients Treated with CyberKnife(R) System 3Health News:Genetics and Risk, This Week on Your Cancer Today(TM) 2Health News:Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V. 2Health News:Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 2Health News:Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 3Health News:Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 4Health News:National Council on Disability (NCD) Hosts Quarterly Meeting 2Health News:National Council on Disability (NCD) Hosts Quarterly Meeting 3Health News:In Progressive Move, 21st Services Forms Independent Medical Advisory Board to Study Longevity, Mortality Risk 2
... Control of thumb motion can be ... stroke, for persons with spinal cord injuries ... due to cerebral palsy or other motor ... positions the thumb for control and coordination. ...
... stabilizes the MP joint and the CMC joint of ... of both of the thumb joints. An excellent choice ... but who need maximum mobility for daily activities. Ideal ... thumb and for those with pain due to repetitive ...
... profile contour at the palmar crease to allow ... excellent choice to treat mild to moderate wrist ... wear following cast removal. The lightweight laminated ... fasteners provides support and compression to the wrist ...
... common site for arthritis in the hand. The ... the wrist or other joints of the thumb. ... or reduce subluxation of the CMC joint of ... without pain. Also useful for persons experiencing pain ...
Medicine Products: